• Moderna for cancer gene therapy, but still clinical-stage.
• CRISPR Therapeutics for cancer gene therapy, but still clinical-stage.

Genprex (GNPX) Major Products:

• REQORSA® (quprelvir): An investigational immunogene therapy designed to deliver a tumor suppressor gene to cancer cells, currently in clinical trials for non-small cell lung cancer and other cancers.
• GPX-001 (Immunoprox™): An investigational gene therapy being developed to activate the immune system for the potential treatment of pancreatic cancer and melanoma.
• GPX-002: An investigational gene therapy designed to activate the immune system for the potential treatment of glioblastoma.

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing innovative therapies for cancer and other diseases. As a clinical-stage biotechnology company, Genprex does not currently have any commercialized products on the market.

Therefore, Genprex does not have major customers (either other companies or individuals) purchasing its products in the traditional commercial sense. Its operations are centered around research, development, and conducting clinical trials.

Instead of customers, Genprex's key relationships are with:

• Research institutions and academic medical centers that collaborate on preclinical studies and clinical trials.
• Strategic partners for the development and potential commercialization of its drug candidates (e.g., licensing agreements), rather than direct product sales.
• Patients participating in its ongoing clinical trials, who receive the investigational therapies as part of the research process, not as commercial purchasers.

The concept of "major customers" as described in the prompt does not apply to Genprex at its current stage of development.

null

Ryan M. Confer, President, Chief Executive Officer, and Chief Financial Officer

Ryan M. Confer was appointed President and Chief Executive Officer of Genprex in May 2024 and has served as Chief Financial Officer since September 2016. He previously held the roles of Chief Operating and Financial Officer from December 2013 to September 2016, and business manager from June 2011 to December 2013. Mr. Confer has been involved with Genprex since its inception in 2009 in various strategic, operations, and finance capacities, both as a consultant through his firm, Confer Capital, Inc., and as an employee. He possesses over a decade of entrepreneurial experience in planning, launching, developing, and growing emerging technology companies, serving in c-level and vice president roles since 2008. Notably, he was VP of Customer Experience and later VP of Strategy for KaiNexus, Inc., a company developing continuous improvement software. Prior to his entrepreneurial endeavors, Mr. Confer worked as a business development consultant for the University of Texas at Austin's IC2 Institute, evaluating the commercialization potential of nascent technologies. From 2006 to 2009, he served as a portfolio manager for a $500 million early-stage technology investment fund. He has experience structuring and negotiating deal terms for financing and licensing transactions.

Mark Berger, M.D., Chief Medical Officer

Dr. Mark Berger joined Genprex in September 2021 as Chief Medical Officer. He is a senior executive with 25 years of experience in biotech and pharmaceutical companies, focusing on the development of oncology therapeutics. Before Genprex, Dr. Berger was Chief Medical Officer for Actinium Pharmaceuticals, Inc., where he was responsible for clinical strategy and development of radioisotope-labeled antibodies for oncology therapy. He also served as Senior Vice President-Clinical Research at Kadmon Corporation, leading new drug development and oncology programs. Earlier in his career, he was Chief Medical Officer of Deciphera Pharmaceuticals and Vice President for Clinical Development at Gemin X Pharmaceuticals, which was acquired by Cephalon in March 2011 based on clinical trial results he led. Dr. Berger also held key positions at GlaxoSmithKline, managing the development of Tykerb (lapatinib), and at Wyeth Research, where he led the pivotal Phase 2 trial for Mylotarg. He is board certified in internal medicine, hematology, and medical oncology.

Thomas Gallagher, Esq., Senior Vice President of Intellectual Property & Licensing

Thomas C. Gallagher has more than 25 years of experience as an intellectual property attorney. Prior to joining Genprex, he was a Principal at the Fenagh Group, an IP and licensing consultancy. He also served as Senior Vice President of Intellectual Property and Licensing at Kadmon Corporation, LLC, and as in-house IP counsel at Neostem Inc. (now Caladrius Biosciences, Inc.). Earlier, he held several positions at ImClone Systems Incorporated, most recently as Vice President of Intellectual Property and Licensing. At ImClone, he was responsible for all aspects of intellectual property and played a key role in due diligence that led to a $2 billion strategic investment by Bristol Myers Squibb and the eventual sale of the company to Eli Lilly and Company for $6.5 billion.

David M. Schloss, Senior Vice President of Human Resources

David M. Schloss is the Senior Vice President of Human Resources at Genprex. No additional background information on founding or managing other companies, company sales, or private equity backing was readily available in the search results.

Suzanne Thornton-Jones, Ph.D., Senior Vice President, Regulatory Affairs and Quality

Suzanne Thornton-Jones, Ph.D., serves as the Senior Vice President, Regulatory Affairs and Quality at Genprex. No additional background information on founding or managing other companies, company sales, or private equity backing was readily available in the search results.

Genprex (symbol: GNPX) is a clinical-stage gene therapy company with lead product candidates targeting cancer and diabetes. The addressable markets for their main products and services are as follows:

Reqorsa® Gene Therapy (quaratusugene ozeplasmid)

Reqorsa is Genprex's lead product candidate, currently being evaluated in clinical trials for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

• Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer therapeutics market was estimated at USD 20.2 billion in 2024 and is projected to reach USD 53.9 billion by 2034. The U.S. NSCLC market was valued at USD 8.2 billion in 2024.
• Small Cell Lung Cancer (SCLC): The global small cell lung cancer therapeutics market is estimated at USD 6.46 billion in 2024 and is predicted to surpass approximately USD 20.6 billion by 2034. The 7 Major Markets (7MM) for SCLC are expected to reach USD 23.0 billion by 2035.

GPX-002 (Diabetes Gene Therapy)

GPX-002 is Genprex's diabetes gene therapy approach, currently in preclinical development for Type 1 and Type 2 diabetes. The addressable market for diabetes treatment is substantial:

• United States Diabetes Market: Spending related to Type 1 diabetes in the U.S. is expected to reach USD 20.3 billion by 2029. Type 2 diabetes market sales in the U.S. are projected to climb to USD 57 billion by 2029.
• Global Diabetes Patient Population: Roughly 537 million people worldwide are living with diabetes, a figure expected to rise to 783 million by 2045.

NPRL2

NPRL2 is a tumor suppressor gene for which Genprex has filed intellectual property protection, with preclinical research in NSCLC cells. A specific addressable market size for NPRL2 as a distinct product is not identifiable in the provided information.

• Successful Commercialization of Reqorsa™ for Lung Cancer: Genprex's lead oncology product candidate, Reqorsa™ (quaratusugene ozeplasmid), is in clinical development for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The Acclaim-3 trial for SCLC holds FDA Fast Track and Orphan Drug designations. The Phase 2a portion for NSCLC began dosing in January 2024 and is projected to complete enrollment by the end of 2025, with an interim data review anticipated in the first half of 2026. Achieving successful clinical trial outcomes and subsequent regulatory approvals will be crucial for the commercial launch of Reqorsa™ and its contribution to future revenue.
• Advancement and Commercialization of GPX-002 for Diabetes: Genprex is developing GPX-002, a preclinical gene therapy candidate aimed at reprogramming pancreatic cells to restore natural insulin production for both Type 1 and Type 2 diabetes. The successful advancement of this program through clinical trials and eventual commercialization could open up a significant new market and revenue stream for the company.
• Strategic Partnerships and Collaborations: Future revenue growth could be significantly enhanced through strategic partnerships with other pharmaceutical companies or research institutions. These collaborations can provide access to new technologies, additional funding, and specialized expertise, thereby accelerating the development and commercialization of Genprex's pipeline.
• Expansion of Reqorsa™ to Other Solid Tumors and Pipeline Enhancement: Genprex is actively engaged in preclinical research to explore the application of Reqorsa™ in combination with targeted therapies and immunotherapies for other solid tumors, such as ALK-positive NSCLC. Additionally, the company is investigating how other cancer-fighting genes, like NPRL2, can augment its portfolio utilizing the ONCOPREX Delivery System. Broadening the therapeutic applications of its lead candidate and core technology to a wider range of cancers would expand Genprex's total addressable market and potential for future revenue generation.

Share Issuance

• Genprex announced a registered direct offering of up to $10.0 million on October 28, 2025.
• On October 23, 2025, the company announced another registered direct offering of up to $8.2 million.
• In March 2024, Genprex completed a registered direct offering, generating gross proceeds of approximately $6.5 million from the sale of 1,542,112 shares of common stock (or prefunded warrants) and accompanying warrants.

Inbound Investments

• Genprex has received capital through several registered direct offerings, including approximately $6.5 million in March 2024, up to $8.2 million in October 2025, and up to $10.0 million in October 2025.

Capital Expenditures

• Genprex primarily relies on third-party contract development and manufacturing organizations (CDMOs) for the production of its product candidates.
• The company has transferred manufacturing processes from MD Anderson to CDMOs and scaled up clinical production for its Acclaim-1 and Acclaim-3 clinical trials.
• Publicly available financial data often reports "n/a" or a dash for capital expenditures, suggesting these are not significant line items for the company.